Form 4: Salarius Pharmaceuticals CEO Acquires Stock Options
SEC Form 4 Filing
David J. Arthur, CEO of Salarius Pharmaceuticals, acquired 20,500 stock options on April 11, 2024.
Summary
- David J. Arthur, the CEO of Salarius Pharmaceuticals, acquired 20,500 stock options on April 11, 2024.
- The exercise price of these options is $0.51.
- The options become exercisable on April 11, 2025, and expire on April 11, 2034.
- The underlying security for these derivative securities is 20,500 shares of common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it is a standard regulatory filing related to stock option grants.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor management's alignment with shareholder interests.
Stakeholder Impact
- Shareholders can monitor insider transactions to assess management's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 04/11/2024 | Date of earliest transaction: CEO acquired stock options. |
| 04/11/2025 | Stock options become exercisable. |
| 04/11/2034 | Stock options expiration date. |
| 04/12/2024 | Date of signature on the Form 4 filing. |
Keywords
stock options, Form 4, Salarius Pharmaceuticals, SLRX, insider trading, David J. Arthur, CEO, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.